NRx Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.66 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 115.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Details
| Name | NRx Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 29 |
| Founded | 2015 |
| Ceo | Jonathan Javitt |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US6294442099 |
| Cusip | 629444209 |
| Cik | 1719406 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman and Chief Executive Officer |
| Michael S. Abrams M.B.A. | Chief Financial Officer and Treasurer |
| Joseph M. Casper | Chief Operating Officer |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing and Technology Officer |
| Dr. Hervé Perron HDR, Ph.D. | Chief Scientist |
| Suzanne Messere | Investor Relations |
| Michael Taylor | Chief Development Officer and Director |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer and Director |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer |
Contact
| Address | 1201 N. Market Street, Suite 111, Wilmington, Delaware 19801, United States |
| Phone | 484 254 6134 |
| Website | https://www.nrxpharma.com |